As regards immune checkpoints, the use of non-selective HDACi is known to increase the expression of PD-L1 on the cell surface of tumor cells (17, 18), while selective HDAC6i have shown the opposite effect, downregulating the expression of PD-L1. The gene discussed is CD274; the disease is neoplasm.